Coherus BioSciences, Inc. (NASDAQ:CHRS) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Saturday.
Several other research firms also recently weighed in on CHRS. Maxim Group set a $43.00 price target on shares of Coherus BioSciences and gave the stock a “buy” rating in a research report on Monday, May 15th. BMO Capital Markets restated an “outperform” rating and set a $54.00 price target on shares of Coherus BioSciences in a research report on Monday, May 15th. Barclays PLC restated an “overweight” rating and set a $46.00 price target on shares of Coherus BioSciences in a research report on Sunday, May 21st. Citigroup Inc. set a $38.00 price target on shares of Coherus BioSciences and gave the stock a “buy” rating in a research report on Wednesday, May 17th. Finally, ValuEngine upgraded shares of Coherus BioSciences from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. Coherus BioSciences has an average rating of “Buy” and an average price target of $37.11.
Coherus BioSciences (NASDAQ:CHRS) opened at 12.70 on Friday. The stock’s 50 day moving average price is $14.27 and its 200-day moving average price is $20.24. The stock’s market cap is $651.36 million. Coherus BioSciences has a 12 month low of $12.50 and a 12 month high of $31.98.
Coherus BioSciences (NASDAQ:CHRS) last released its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($1.54) earnings per share for the quarter, hitting the consensus estimate of ($1.54). Coherus BioSciences had a negative net margin of 76.85% and a negative return on equity of 827.65%. The firm had revenue of $0.16 million during the quarter. Equities analysts expect that Coherus BioSciences will post ($5.13) EPS for the current year.
TRADEMARK VIOLATION WARNING: This news story was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://stocknewstimes.com/2017/08/07/bidaskclub-lowers-coherus-biosciences-inc-chrs-to-strong-sell.html.
A number of hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC increased its stake in Coherus BioSciences by 32.7% in the second quarter. SG Americas Securities LLC now owns 7,244 shares of the biotechnology company’s stock worth $104,000 after buying an additional 1,785 shares during the last quarter. Legal & General Group Plc increased its stake in Coherus BioSciences by 12.6% in the second quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock worth $134,000 after buying an additional 1,046 shares during the last quarter. Boston Advisors LLC acquired a new stake in Coherus BioSciences during the second quarter worth approximately $244,000. BlueCrest Capital Management Ltd acquired a new stake in Coherus BioSciences during the first quarter worth approximately $246,000. Finally, Jennison Associates LLC increased its stake in Coherus BioSciences by 0.4% in the second quarter. Jennison Associates LLC now owns 18,200 shares of the biotechnology company’s stock worth $261,000 after buying an additional 69 shares during the last quarter. Institutional investors own 72.07% of the company’s stock.
Coherus BioSciences Company Profile
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
